Capsaicin in Treatment of Rhinogenic Headache

Sponsor
University of Nebraska (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT03330639
Collaborator
(none)
36
2
41

Study Details

Study Description

Brief Summary

Description: Capsaicin (8- methyl-N-vanillyl-6-nonenamide) has been demonstrated to have a therapeutic effect in idiopathic rhinitis. We hypothesize that capsaicin has a therapeutic effect on rhinogenic headaches, in addition to the previously studied decongestive effects. This study aims to evaluate capsaicin impact on headaches attributed to V1, V2 distribution of the sinonasal cavity. This study is a randomized, double-blinded, parallel trial.

Condition or Disease Intervention/Treatment Phase
  • Other: Capsaicin
  • Other: Placebo
N/A

Detailed Description

  1. Title: The role of capsaicin in treatment of rhinogenic headache

  2. Description: Capsaicin (8- methyl-N-vanillyl-6-nonenamide) has been demonstrated to have a therapeutic effect in idiopathic rhinitis, migraines and cluster headaches. We hypothesize that capsaicin has a therapeutic effect on rhinogenic headaches as well. This study aims to evaluate capsaicin impact on headaches attributed to the nose and paranasal sinus distribution.

  3. Interventions, evaluations, and follow-up: Subjects are recruited from an Otolaryngology clinic, where a formal headache questionnaire is administered in-office, and standard endoscopy is performed in office to rule out confounding causes of headache and sinonasal disease. Written instructions are provided and consent obtained. A symptom journal is provided. Subjects are randomly selected to receive two bottles of either eucalyptol spray (placebo) or sinus buster (capsaicin) spray and are blinded to the content of the spray bottle. They are instructed to use the nasal spray one to two times daily. Subjects are permitted to continue to take headache medication as needed, but it must be recorded in their symptom journal. The journal is completed daily, and includes medication use, a headache pain score, and side effect log. Additionally, subjects fill out SinoNasal Outcome test (SNOT)22 at 2 weeks, 4 weeks, and 8 weeks. Weekly emails are sent to remind subject to fill out their journal. A phone call is made to the subject to survey them on progress at 2 and 6 weeks. Follow up visits are scheduled at 4 weeks and 8 weeks, or sooner if problems arise. A standard nasal endoscopy is performed at the first and last visit.

  4. Additional data that would be tracked: Quality of life score as measured by SNOT-22 scores, treatment failure and drop-outs, and objective changes in sinus endoscopy.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
36 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Intervention Model Description:
Randomized parallel groupRandomized parallel group
Masking:
Single (Participant)
Primary Purpose:
Treatment
Official Title:
The Role of Topical Capsaicin in Treatment of Rhinogenic Headache
Anticipated Study Start Date :
Jul 1, 2020
Anticipated Primary Completion Date :
May 1, 2022
Anticipated Study Completion Date :
Dec 1, 2023

Arms and Interventions

Arm Intervention/Treatment
Experimental: Experimental Group

This group will receive the capsaicin. The Study Drug ICX72 or sinus buster which is a homeopathic blend of capsicum annum and eucalyptol, that is readily available over the counter.

Other: Capsaicin
Capsaicin is a homeopathic medication and there for this drug is not subject to the requirements of the FDA.

Placebo Comparator: Placebo Group

This group will receive saline. The Placebo formulation contained saline and eucalyptol in a concentration that matched the control.

Other: Placebo
This group will receive the saline placebo solution.

Outcome Measures

Primary Outcome Measures

  1. headache medication use [1 year]

    We will track the amount of headache medication used during the study period

Secondary Outcome Measures

  1. number of patients with treatment related adverse events [1 year]

    patients will be asked to report any adverse reactions or events during the study period.

  2. headache frequency and severity [1 year]

    Patient will be asked to record the number of headaches during the study period, and record the severity from 1-10 on the Visual Analog Scale (VAS)

Eligibility Criteria

Criteria

Ages Eligible for Study:
19 Years to 100 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • Consenting Adults aged 19-100 presenting to the Otolaryngology DepartmentofUniversityof Nebraska Medical center complaining of headaches/ facial pain and pressure Diagnosis of a primary rhinogenic headache disorder by the senior authors.
Exclusion Criteria:
  • Exclusion criteria include: pregnancy, age less than 19, active history of smoking, presence of confirmed sinonasal disease, fibromyalgia, poorly controlled chronic health problems, allergies to chili peppers or any ingredient in the nasal spray, or confirmed Temporal Mandibular Joint (TMJ) arthralgia as the etiology of primary headache.

Contacts and Locations

Locations

No locations specified.

Sponsors and Collaborators

  • University of Nebraska

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Additional Information:

Publications

Responsible Party:
Karli Davis, PI, University of Nebraska
ClinicalTrials.gov Identifier:
NCT03330639
Other Study ID Numbers:
  • 511-17
First Posted:
Nov 6, 2017
Last Update Posted:
May 8, 2020
Last Verified:
May 1, 2020
Individual Participant Data (IPD) Sharing Statement:
Undecided
Plan to Share IPD:
Undecided
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of May 8, 2020